Discovery of epidermal/dermal targeting formulations for cutaneous squamous cell carcinoma

$2.52M USD

Funder	NATIONAL CANCER INSTITUTE
Recipient Organization	Via Therapeutics, Llc
Country	United States
Start Date	Jul 12, 2021
End Date	Jun 30, 2024
Duration	1,084 days
Number of Grantees	2
Roles	Co-Investigator; Principal Investigator
Data Source	NIH (US)
Grant ID	`10259286`

Grant Description

The incidence and mortality rates of cutaneous squamous cell carcinoma (cSCC) and skin cancer continues to increase. It is expected that 1 in 5 Americans will develop skin cancer in their lifetime. Although surgical excision is typically indicated and effective, surgery is not always appropriate or possible.

Efforts to treat and/or prevent using pharmacological agents are limited by poor delivery to the site of action (the skin epidermis and dermis) and majority of the pharmacological therapy involves systemic administration with few topical agents available.

Existing drugs and combinations of natural compounds with potential to be used against skin cancer, including cSCC, have